Mary Scholand, MD
Pulmonary Disease · Salt Lake City, UTNPI 1639269251
Payments from drug & device makers
Across 788 payments — averaging $3863.46 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- United Therapeutics Corporation$920K
- Boehringer Ingelheim$914K
- Roche Products Limited$597K
- E.r. Squibb & Sons, L.L.C.$196K
- Novartis$124K
- Bristol Myers Squibb$70K
- plus $223K from 14 others
Across 11 payments — averaging $5307.64 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Boehringer Ingelheim International GmbH$43K
- F. Hoffmann-la Roche AG$10K
- United Therapeutics Corporation$5K
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| United Therapeutics Corporation | 288 | $919,926 |
| Boehringer Ingelheim | 138 | $914,279 |
| Roche Products Limited | 26 | $596,819 |
| E.r. Squibb & Sons, L.L.C. | 6 | $196,127 |
| Novartis | 4 | $124,422 |
| Bristol Myers Squibb | 4 | $70,122 |
| Genentech, Inc. | 13 | $69,718 |
| GSK | 13 | $42,730 |
| Daiichi Sankyo Inc. | 34 | $35,891 |
| Mallinckrodt Enterprises LLC | 1 | $23,214 |
| Boehringer Ingelheim International GmbH | 88 | $18,336 |
| Boehringer Ingelheim France S.a.s. | 59 | $12,648 |
| Boehringer Ingelheim Pharma GmbH & Co.kg | 72 | $7,821 |
| Genentech USA, Inc. | 10 | $6,155 |
| AbbVie | 2 | $3,018 |
| Merck | 11 | $1,413 |
| Boehringer Ingelheim Limited | 9 | $926 |
| Insmed, Inc. | 8 | $506 |
| Kadmon Corporation LLC | 1 | $303 |
| Sandoz | 1 | $35 |
How this compares
$3,044,408 in reported general payments places this provider in the 95th percentile of 101 pulmonary disease providers in Utah.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Other pulmonary disease in Salt Lake City
- Mark MartinezSalt Lake City$261K
- Erin BlackstockSalt Lake City$249K
- Jason CarrSalt Lake City$134K
- Chakravarthy ReddySalt Lake City$95K
- James PearlSalt Lake City$69K
- Richard KannerSalt Lake City$68K
- Jefferson ChambersSalt Lake City$57K
- Andrew FreemanSalt Lake City$52K
- Edward CampbellSalt Lake City$40K
- Lara HardmanSalt Lake City$37K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.